Skip to main content
×
×
Home

Extrapyramidal side-effects of antipsychotics in a randomised trial

  • Del D. Miller (a1), Stanley N. Caroff (a2), Sonia M. Davis (a3), Robert A. Rosenheck (a4), Joseph P. McEvoy (a5), Bruce L. Saltz (a6), Silvana Riggio (a7), Miranda H. Chakos (a8), Marvin S. Swartz (a5), Richard S.E. Keefe (a5), T. Scott Stroup (a9), Jeffrey A. Lieberman (a10) and for the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators...
Abstract
Background

There are claims that second-generation antipsychotics produce fewer extrapyramidal side-effects (EPS) compared with first-generation drugs.

Aims

To compare the incidence of treatment-emergent EPS between second-generation antipsychotics and perphenazine in people with schizophrenia.

Method

Incidence analyses integrated data from standardised rating scales and documented use of concomitant medication or treatment discontinuation for EPS events. Mixed model analyses of change in rating scales from baseline were also conducted.

Results

There were no significant differences in incidence or change in rating scales for parkinsonism, dystonia, akathisia or tardive dyskinesia when comparing second-generation antipsychotics with perphenazine or comparing between second-generation antipsychotics. Secondary analyses revealed greater rates of concomitant antiparkinsonism medication among individuals on risperidone and lower rates among individuals on quetiapine, and lower rates of discontinuation because of parkinsonism among people on quetiapine and ziprasidone. There was a trend for a greater likelihood of concomitant medication for akathisia among individuals on risperidone and perphenazine.

Conclusions

The incidence of treatment-emergent EPS and change in EPS ratings indicated that there are no significant differences between second-generation antipsychotics and perphenazine or between second-generation antipsychotics in people with schizophrenia.

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Extrapyramidal side-effects of antipsychotics in a randomised trial
      Available formats
      ×
      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Extrapyramidal side-effects of antipsychotics in a randomised trial
      Available formats
      ×
      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Extrapyramidal side-effects of antipsychotics in a randomised trial
      Available formats
      ×
Copyright
Corresponding author
Del D. Miller, University of Iowa Carver College of Medicine, Psychiatry Research, #2-105 MEB, 500 Newton Road, Iowa City, IA 52242–1000, USA. Email: del-miller@uiowa.edu
References
Hide All
1 Arvanitis, LA, Miller, BG. Multiple fixed doses of “Seroquel” (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group. Biol Psychiatry 1997; 42: 233–46.
2 Daniel, DG, Zimbroff, DL, Potkin, SG, Reeves, KR, Harrigan, EP, Lakshminarayanan, M. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group. Neuropsychopharmacology 1999; 20: 491505.
3 Kane, JM, Woerner, M, Lieberman, J. Prevalence, incidence, and risk factors. J Clin Psychopharmacol 1988; 8 (suppl): 52–6.
4 Marder, SR, Meibach, RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994; 151: 825–35.
5 Potkin, SG, Saha, AR, Kujawa, MJ, Carson, WH, Ali, M, Stock, E, Stringfellow, J, Ingenito, G, Marder, SR. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 2003; 60: 681–90.
6 Tollefson, GD, Sanger, TM. Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine. Am J Psychiatry 1997; 154: 466–74.
7 Geddes, J, Freemantle, N, Harrison, P, Bebbington, P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 2000; 321: 1371–6.
8 Davis, JM, Chen, N, Glick, ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 2003; 60: 553–64.
9 Jones, PB, Barnes, TR, Davies, L, Dunn, G, Lloyd, H, Hayhurst, KP, Murray, RM, Markwick, A, Lewis, SW. Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry 2006; 63: 1079–87.
10 Rosenheck, R, Perlick, D, Bingham, S, Liu-Mares, W, Collins, J, Warren, S, Leslie, D, Allan, E, Campbell, EC, Caroff, S, Corwin, J, Davis, L, Douyon, R, Dunn, L, Evans, D, Frecska, E, Grabowski, J, Graeber, D, Herz, L, Kwon, K, Lawson, W, Mena, F, Sheikh, J, Smelson, D, Smith-Gamble, V. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial. JAMA 2003; 290: 2693–702.
11 Leucht, S, Wahlbeck, K, Hamann, J, Kissling, W. New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet 2003; 361: 1581–9.
12 Hugenholtz, GW, Heerdink, ER, Stolker, JJ, Meijer, WE, Egberts, AC, Nolen, WA. Haloperidol dose when used as active comparator in randomized controlled trials with atypical antipsychotics in schizophrenia: comparison with officially recommended doses. J Clin Psychiatry 2006; 67: 897903.
13 Rosenheck, R, Stroup, S, Keefe, RSE, McEvoy, J, Swartz, M, Perkins, D, Hsiao, J, Shumway, M, Lieberman, J. Measuring outcome priorities and preferences in people with schizophrenia. Br J Psychiatry 2005; 187: 529–36.
14 Correll, CU, Leucht, S, Kane, JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry 2004; 161: 414–25.
15 Chouinard, G, Annable, L, Mercier, P, Ross-Chouinard, A. A five year follow-up study of tardive dyskinesia. Psychopharmacol Bull 1986; 22: 259–63.
16 Glazer, WM. Review of incidence studies of tardive dyskinesia associated with typical antipsychotics. J Clin Psychiatry 2000; 61 (suppl 4): 1520.
17 Glazer, WM, Morgenstern, H, Doucette, JT. Predicting the long-term risk of tardive dyskinesia in outpatients maintained on neuroleptic medications. J Clin Psychiatry 1993; 54: 133–9.
18 Kane, JM, Woerner, M, Weinhold, P, Wegner, J, Kinon, B, Borenstein, M. Incidence of tardive dyskinesia: five-year data from a prospective study. Psychopharmacol Bull 1984; 20: 387–9.
19 Miller, DD, McEvoy, JP, Davis, SM, Caroff, SN, Saltz, BL, Chakos, MH, Swartz, MS, Keefe, RS, Rosenheck, RA, Stroup, TS, Lieberman, JA. Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial. Schizophr Res 2005; 80: 3343.
20 Lieberman, JA, Stroup, TS, McEvoy, JP, Swartz, MS, Rosenheck, RA, Perkins, DO, Keefe, RS, Davis, SM, Davis, CE, Lebowitz, BD, Severe, J, Hsiao, JK. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353: 1209–23.
21 Simpson, GM, Angus, JWS. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand 1970; 212: 11–9.
22 Barnes, TR. A rating scale for drug-induced akathisia. Br J Psychiatry 1989; 154: 672–6.
23 Guy, W. Abnormal involuntary movement scale (AIMS). In ECDEU Assessment Manual for Psychopharmacology Revised: 534–7. Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, 1976.
24 Stroup, TS, Lieberman, JA, McEvoy, JP, Swartz, MS, Davis, SM, Capuano, GA, Rosenheck, RA, Keefe, RS, Miller, AL, Belz, I, Hsiao, JK. Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study. Am J Psychiatry 2007; 164: 415–27.
25 Stroup, TS, McEvoy, JP, Swartz, MS, Byerly, MJ, Glick, ID, Canive, JM, McGee, MF, Simpson, GM, Stevens, MC, Lieberman, JA. The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. Schizophr Bull 2003; 29: 1531.
26 Schooler, NR, Kane, JM. Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry 1982; 39: 486–7.
27 Hochberg, Y. A shaper Bonferroni procedure for multiple tests of significance. Biometrika 1988; 75: 800–3.
28 Stokes, ME, Davis, CS, Koch, GG. Categorical Data Analysis Using the SAS System. SAS Institute Inc, 2000.
29 Chakos, MH, Alvir, JM, Woerner, MG, Koreen, A, Geisler, S, Mayerhoff, D, Sobel, S, Kane, JM, Borenstein, M, Lieberman, JA. Incidence and correlates of tardive dyskinesia in first episode of schizophrenia. Arch Gen Psychiatry 1996; 53: 313–9.
30 Fenton, WS. Prevalence of spontaneous dyskinesia in schizophrenia. J Clin Psychiatry 2000; 61 (suppl 4): 10–4.
31 Eberhard, J, Lindstrom, E, Levander, S. Tardive dyskinesia and antipsychotics: a 5-year longitudinal study of frequency, correlates and course. Int Clin Psychopharmacol 2006; 21: 3542.
32 Gharabawi, GM, Bossie, CA, Zhu, Y. New-onset tardive dyskinesia in patients with first-episode psychosis receiving risperidone or haloperidol. Am J Psychiatry 2006; 163: 938–9.
33 Jeste, DV, Okamoto, A, Napolitano, J, Kane, JM, Martinez, RA. Low incidence of persistent tardive dyskinesia in elderly patients with dementia treated with risperidone. Am J Psychiatry 2000; 157: 1150–5.
34 Lee, C, Wu, KH, Habil, H, Dyachkova, Y, Lee, P. Treatment with olanzapine, risperidone or typical antipsychotic drugs in Asian patients with schizophrenia. Aust N Z J Psychiatry 2006; 40: 437–45.
35 Dolder, CR, Jeste, DV. Incidence of tardive dyskinesia with typical versus atypical antipsychotics in very high risk patients. Biol Psychiatry 2003; 53: 1142–5.
36 Gourzis, P, Polychronopoulos, P, Papapetropoulos, S, Assimakopoulos, K, Argyriou, AA, Beratis, S. Quetiapine in the treatment of focal tardive dystonia induced by other atypical antipsychotics: a report of 2 cases. Clin Neuropharmacol 2005; 28: 195–6.
37 Grant, MJ, Baldessarini, RJ. Possible improvement of neuroleptic-associated tardive dyskinesia during treatment with aripiprazole. Ann Pharmacother 2005; 39: 1953.
38 Haro, JM, Salvador-Carulla, L. The SOHO (Schizophrenia Outpatient Health Outcome) study: implications for the treatment of schizophrenia. CNS Drugs 2006; 20: 293301.
39 Kinon, BJ, Jeste, DV, Kollack-Walker, S, Stauffer, V, Liu-Seifert, H. Olanzapine treatment for tardive dyskinesia in schizophrenia patients: a prospective clinical trial with patients randomized to blinded dose reduction periods. Prog Neuropsychopharmacol Biol Psychiatry 2004; 28: 985–96.
40 Spivak, B, Mester, R, Abesgaus, J, Wittenberg, N, Adlersberg, S, Gonen, N, Weizman, A. Clozapine treatment for neuroleptic-induced tardive dyskinesia, parkinsonism, and chronic akathisia in schizophrenic patients. J Clin Psychiatry 1997; 58: 318–22.
41 Tarsy, D, Baldessarini, RJ. Epidemiology of tardive dyskinesia: is risk declining with modern antipsychotics? Mov Disord 2006; 21: 589–98.
42 Kane, JM, Leucht, S, Carpenter, D, Docherty, JP; for the Expert Consensus Panel for Optimizing Pharmacologic Treatment of Psychotic Disorders. The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary. J Clin Psychiatry 2003; 64 (suppl 12): 519.
43 Rosenheck, RA, Leslie, DL, Sindelar, J, Miller, EA, Lin, H, Stroup, TS, McEvoy, J, Davis, SM, Keefe, RS, Swartz, M, Perkins, DO, Hsiao, JK, Lieberman, J. Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. Am J Psychiatry 2006; 163: 2080–9.
44 Swartz, MS, Perkins, DO, Stroup, TS, Davis, SM, Capuano, G, Rosenheck, RA, Reimherr, F, McGee, MF, Keefe, RS, McEvoy, JP, Hsiao, JK, Lieberman, JA. Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study. Am J Psychiatry 2007; 164: 428–36.
45 Keefe, RS, Bilder, RM, Davis, SM, Harvey, PD, Palmer, BW, Gold, JM, Meltzer, HY, Green, MF, Capuano, G, Stroup, TS, McEvoy, JP, Swartz, MS, Rosenheck, RA, Perkins, DO, Davis, CE, Hsiao, JK, Lieberman, JA. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch Gen Psychiatry 2007; 64: 633–47.
46 Kelsey, JL, Whittemore, AS, Evans, AS, Thompson, DS. Methods in Observational Epidemiology (2nd edn): 88–9. Oxford University Press, 1996.
47 Crane, GE. Prevention and management of tardive dyskinesia. Am J Psychiatry 1972; 129: 466–7.
48 Kane, JM, Woerner, M, Borenstein, M, Wegner, J, Lieberman, J. Integrating incidence and prevalence of tardive dyskinesia. Psychopharmacol Bull 1986; 22: 254–8.
49 Saltz, BL, Woerner, MG, Kane, JM, Lieberman, JA, Alvir, JM, Bergmann, KJ, Blank, K, Koblenzer, J, Kahaner, K. Prospective study of tardive dyskinesia incidence in the elderly. JAMA 1991; 266: 2402–6.
50 Umbricht, D, Kane, JM. Medical complications of new antipsychotic drugs. Schizophr Bull 1996; 22: 475–83.
51 Rosenheck, R, Stroup, T, Swartz, M, Mcevoy, J, Davis, S, Keefe, R, Hsiao, J, Lieberman, J. Dr. Rosenheck and Colleagues Reply. Am J Psychiatry 2007; 164: 678–80.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

The British Journal of Psychiatry
  • ISSN: 0007-1250
  • EISSN: 1472-1465
  • URL: /core/journals/the-british-journal-of-psychiatry
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×
Type Description Title
PDF
Supplementary materials

Miller et al. supplementary material
Supplementary Material

 PDF (299 KB)
299 KB
UNKNOWN
Supplementary materials

Miller et al. supplementary material
Supplementary Material

 Unknown (488 bytes)
488 bytes

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed

Extrapyramidal side-effects of antipsychotics in a randomised trial

  • Del D. Miller (a1), Stanley N. Caroff (a2), Sonia M. Davis (a3), Robert A. Rosenheck (a4), Joseph P. McEvoy (a5), Bruce L. Saltz (a6), Silvana Riggio (a7), Miranda H. Chakos (a8), Marvin S. Swartz (a5), Richard S.E. Keefe (a5), T. Scott Stroup (a9), Jeffrey A. Lieberman (a10) and for the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators...
Submit a response

eLetters

No eLetters have been published for this article.

×

Reply to: Submit a response


Your details


Conflicting interests

Do you have any conflicting interests? *